TY - JOUR
T1 - Chimeric Antigen Receptor Therapy
T2 - How Are We Driving in Solid Tumors?
AU - Greenbaum, Uri
AU - Yalniz, Fevzi F.
AU - Srour, Samer A.
AU - Rezvani, Katayoun
AU - Singh, Harjeet
AU - Olson, Amanda
AU - Blumenschein, George
AU - Hong, David S.
AU - Shpall, Elizabeth J.
AU - Kebriaei, Partow
N1 - Funding Information:
Financial disclosure: U.G. is the recipient of a Fellowship Grant from the American Physicians Fellowship for Medicine in Israel. Conflict of interest statement: E.J.S. serves on the scientific advisory boards of Magenta, Novartis, Celgene, Adaptimmune, and Zelluna. K.R. has a licensing agreement with Takeda; has received educational grants from Affymed and Pharmacyclics; and serves on scientific advisory boards of Virogen, Adicet Bio, Formula Pharma, and GemoAb. G.B. reports grants from Adaptimmune, Elelixis, GlaxoSmithKline, Immatics, Immunocore, Incyte, Kite Pharma, Macrogenics, and Torque; personal fees from Clovis Oncology, Abbvie, Adicet, Amgen, Ariad, Virogin Biotech, Johnson & Johnson/Janssen, and Maverick Therapeutics; and grants and personal fees from Novartis, Bayer, AstraZeneca, Bristol-Myers Squibb, Celgene, Genetech, MedImmune, Merck, Roche, and Xcovery. D.S.H. reports research/grant funding from AbbVie, Adaptimmune, Aldi-Norte, Amgen, Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GSK, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, miRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda, Turning Point Therapeutics; has received reimbursement for travel, accommodations, and expenses from Bayer, Genmab, AACR, ASCO, SITC. Consulting or Advisory Role: Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H, Guidepoint, Infinity, Medscape, Numab, Oncology Education Project Association, Pfizer, Prime Oncology, Takeda, Trieza Therapeutics, and WebMD; and has other ownership interests in Molecular Match (advisor), OncoResponse (founder), and Presagia (advisor). P.K. has received research support from Amgen and Ziopharm; has served on advisory boards for Pfizer, Kite, and Novartis; and has received consulting fees from Jazz Pharmaceuticals. Financial disclosure: See Acknowledgments on page 1768.
Funding Information:
Financial disclosure: U.G. is the recipient of a Fellowship Grant from the American Physicians Fellowship for Medicine in Israel.
Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy
PY - 2020/10
Y1 - 2020/10
N2 - Immune effector cell (IEC) therapy is emerging as a promising approach in the field of cancer immunotherapy. Clinical IEC trials, predominantly using chimeric antigen receptor (CAR) T cells, have shown excellent responses in CD19+ B cell malignancies and multiple myeloma. In solid tumors, preclinical data are encouraging, but clinical data are in their infancy, and there are challenges in using CAR T therapy in this setting, including (1) on-target off-tumor toxicity, (2) optimal target identification, (3) effective trafficking into bulky tumor tissue, and (4) resistance to tumor immune evasion mechanisms. Novel techniques and modifications are being explored in both the preclinical and clinical settings, aiming to improve treatment efficacy and address the aforementioned obstacles to successful CAR T therapy in solid tumors. Here we review these challenges in a clinically oriented approach and summarize published clinical trials using CAR T therapy in a variety of solid tumors.
AB - Immune effector cell (IEC) therapy is emerging as a promising approach in the field of cancer immunotherapy. Clinical IEC trials, predominantly using chimeric antigen receptor (CAR) T cells, have shown excellent responses in CD19+ B cell malignancies and multiple myeloma. In solid tumors, preclinical data are encouraging, but clinical data are in their infancy, and there are challenges in using CAR T therapy in this setting, including (1) on-target off-tumor toxicity, (2) optimal target identification, (3) effective trafficking into bulky tumor tissue, and (4) resistance to tumor immune evasion mechanisms. Novel techniques and modifications are being explored in both the preclinical and clinical settings, aiming to improve treatment efficacy and address the aforementioned obstacles to successful CAR T therapy in solid tumors. Here we review these challenges in a clinically oriented approach and summarize published clinical trials using CAR T therapy in a variety of solid tumors.
KW - Cancer immunotherapy
KW - Chimeric antigen receptor T cells
KW - Immune effector cell therapy
KW - Solid tumor
KW - T cell receptor
UR - http://www.scopus.com/inward/record.url?scp=85088364286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088364286&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2020.06.020
DO - 10.1016/j.bbmt.2020.06.020
M3 - Review article
C2 - 32623078
AN - SCOPUS:85088364286
SN - 1083-8791
VL - 26
SP - 1759
EP - 1769
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 10
ER -